← Back to patent-cliff list
Oremepermin alfa
Tier C — Watch / tradeOremepermin alfa
Kringle Pharma
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：MetRS
Brand：ChronSeal
Indications (approved)：声带功能障碍, Spinal cord injury, Dental caries
Regional status
US
-
EU
No progress
2008-11-01
China
-
Japan
Phase III
2020-07-13
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Oremepermin alfa?
Approved indications include: 声带功能障碍, Spinal cord injury, Dental caries.
When does the Oremepermin alfa patent expire?
No public expiry year is available for Oremepermin alfa yet; this page updates once verified.
How do I get a quote for Oremepermin alfa intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06